Paricalcitol on Albuminuria, Inflammation and Fibrosis on Proteinuric Chronic Renal Diseases (PALIFE Study)

Inclusion Criteria: * Informed consent signed * Patients will be men or women, between 18 and 75 years old. * Patients must have been taken an stable dosis of Angiotensine Converter Enzyme Inhibitor, Angiotensine Receptor Antagonism or antialdosterone at last 6 months before screening visit. * Patients should not be on dialysis treatment. * Women should not be pregnant, or in fertile period (at last 1 year postmenopausal or chirurgic sterilized or using this contraceptive methods: condoms, gel, intrauterine devices, anticonceptives, etc. During at last 3 months after the study beginning. Exclusion Criteria: * Patients have taken active vitamin D during 6 months after the screening. * Patients with allergy o sensibility to paricalcitol. * Patients with acute CKD 12 weeks before the screening. * Patients with chronical gastrointestinal disease. * Patients with hypo or hyperthyroidism. * Patients with secondary hypertension * Bad controled hypertension patients * Patients with renal lithiasis * Patients with drug dependence * Patients taking calcitonins, biphosphonates, cinacalcet or others Ca-metabolism drugs. * Patients taking immunosuppressor drugs. * Patients not adequate to study as medical opinion. * HIV patients * Seric P \> 5.0 mg/dl. * Seric Ca\> 10,0 mg/dl. * Proteinuria \> 3.500 mg/g * Hypoalbuminemia \< 3g/dl